Trials / Completed
CompletedNCT01833130
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OnabotulinumtoxinA | OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12. |
| DRUG | Normal saline (placebo) | Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12. |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-04-16
- Last updated
- 2015-10-21
- Results posted
- 2015-10-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01833130. Inclusion in this directory is not an endorsement.